Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 3350 of 3499 entries
View as:

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00450749 Org: User:
Start: 02/29/08 End: 05/31/10 Due: 05/31/11

A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT00001298 Org: User:
Start: 03/31/92 End: 01/31/01 Due: 01/31/02

Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma

Phase: N/A Priority: Normal
NCT ID: NCT00003909 Org: User:
Start: 08/31/99 End: - Due: -

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00063934 Org: User:
Start: 05/31/03 End: 02/29/08 Due: 02/28/09

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase: N/A Priority: Normal
NCT ID: NCT04739800 Org: User:
Start: 06/10/21 End: 06/14/25 Due: 06/14/26

Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00019773 Org: User:
Start: 07/31/99 End: - Due: -

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT04729959 Org: User:
Start: 03/11/22 End: 08/14/25 Due: 08/14/26

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01087333 Org: User:
Start: 03/02/10 End: - Due: -

Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

Phase: N/A Priority: Normal
NCT ID: NCT02134925 Org: User:
Start: 06/23/14 End: 03/06/26 Due: 03/06/27

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01088763 Org: User:
Start: 03/31/10 End: 05/31/11 Due: 05/31/12

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05898828 Org: User:
Start: 08/02/24 End: 08/02/24 Due: 08/02/25

Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)

Phase: N/A Priority: Normal
NCT ID: NCT01207687 Org: User:
Start: 10/31/10 End: 03/31/14 Due: 03/31/15

Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00290758 Org: User:
Start: 01/31/06 End: 07/31/09 Due: 07/31/10

EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00028782 Org: User:
Start: 10/31/01 End: - Due: -

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00005961 Org: User:
Start: 06/30/00 End: - Due: -

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05673200 Org: User:
Start: 09/25/23 End: 02/23/27 Due: 02/23/28

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT01176006 Org: User:
Start: 10/05/10 End: 12/31/26 Due: 12/31/27

Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02153957 Org: User:
Start: 08/21/14 End: 02/14/23 Due: 02/14/24

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Phase: N/A Priority: Normal
NCT ID: NCT05531786 Org: User:
Start: 03/06/23 End: 07/22/25 Due: 07/22/26

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Phase: N/A Priority: Normal
NCT ID: NCT03964090 Org: User:
Start: 06/27/19 End: 07/01/26 Due: 07/01/27

Celecoxib in Preventing Skin Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00025051 Org: User:
Start: - End: - Due: -

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00553332 Org: User:
Start: 11/30/07 End: 01/31/13 Due: 01/31/14

Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00023920 Org: User:
Start: 07/31/01 End: - Due: -

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04458909 Org: User:
Start: 12/09/20 End: 08/15/23 Due: 08/15/24

Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00055692 Org: User:
Start: 02/28/03 End: 12/31/09 Due: 12/31/10